1274 related articles for article (PubMed ID: 36858871)
1. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
[TBL] [Abstract][Full Text] [Related]
3. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
[TBL] [Abstract][Full Text] [Related]
4. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
5. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
[TBL] [Abstract][Full Text] [Related]
7. Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
Lavender B; Hooker C; Frampton C; Williams M; Carson S; Paterson A; McGregor R; Moreland NJ; Gell K; Priddy FH; Wiig K; Le Gros G; Ussher JE; Brewerton M
Vaccine; 2023 Aug; 41(38):5535-5544. PubMed ID: 37516574
[TBL] [Abstract][Full Text] [Related]
8. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and reactogenicity of repeated intradermal mRNA COVID-19 vaccines administered as a second booster dose in a Thai geriatric population.
Assantachai P; Niyomnaitham S; Toh ZQ; Thammasalee M; Pengsorn N; Monklang W; Licciardi PV; Chokephaibulkit K
Front Immunol; 2023; 14():1302041. PubMed ID: 38274835
[TBL] [Abstract][Full Text] [Related]
10. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
[TBL] [Abstract][Full Text] [Related]
11. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
Wanlapakorn N; Kanokudom S; Phowatthanasathian H; Chansaenroj J; Suntronwong N; Assawakosri S; Yorsaeng R; Nilyanimit P; Vichaiwattana P; Klinfueng S; Thongmee T; Aeemjinda R; Khanarat N; Srimuan D; Thatsanatorn T; Chantima W; Pakchotanon P; Duangchinda T; Sudhinaraset N; Poovorawan Y
J Med Virol; 2023 May; 95(5):e28758. PubMed ID: 37212319
[TBL] [Abstract][Full Text] [Related]
14. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
[TBL] [Abstract][Full Text] [Related]
16. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
[TBL] [Abstract][Full Text] [Related]
17. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
[TBL] [Abstract][Full Text] [Related]
18. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
[TBL] [Abstract][Full Text] [Related]
19. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
[TBL] [Abstract][Full Text] [Related]
20. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
